OXiGENE Announces Presentation of Encouraging OXi4503 Preclinical and Clinical Data in Acute Myelogenous Leukemia at American Society of Hematology Meeting
[at noodls] – SOUTH SAN FRANCISCO, Calif., Dec. 10, 2012 (GLOBE NEWSWIRE) — OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced today that … more
View todays social media effects on OXGN
View the latest stocks trending across Twitter. Click to view dashboard